A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/39 (2006.01) A61K 35/34 (2006.01) A61K 38/28 (2006.01) C12N 5/06 (2006.01) A61K 38/00 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2225185
An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.
Un effet analgésique est obtenu grâce à l'apport continu d'un peptide in vivo, lequel active les récepteurs d'opioïdes ou interfère avec la fixation de la substance P à ses récepteurs. L'apport continu à long terme d'un peptide de ce type peut être réalisé par (a) transduction de cellules myogéniques avec expression du peptide par l'ADN, et (b) administration des cellules myogéniques transduites à un patient, de telle façon que les cellules continuent à produire le peptide.
Law Peter K.
Torys Llp
LandOfFree
Myoblast transfer therapy for relieving pain and for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myoblast transfer therapy for relieving pain and for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myoblast transfer therapy for relieving pain and for... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1837953